LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer

Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients

(2010) P. Hammarsten et al.   CLINICAL CANCER RESEARCH

This title is false

(2009) Mark Isalan et al.   NATURE

Suppression of the Negative Regulator LRIG1 Contributes to ErbB2 Overexpression in Breast Cancer

(2008) J. K. Miller et al.   CANCER RESEARCH

A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer

(2008) Sui Chu Chung et al.   EUROPEAN JOURNAL OF CANCER

Lrig1 Is an Endogenous Inhibitor of Ret Receptor Tyrosine Kinase Activation, Downstream Signaling, and Biological Responses to GDNF

(2008) F. Ledda et al.   JOURNAL OF NEUROSCIENCE

LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking

(2007) A.K. LINDSTRÖM et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER